CBER U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.

Slides:



Advertisements
Similar presentations
The Role of the IRB An Institutional Review Board (IRB) is a review committee established to help protect the rights and welfare of human research subjects.
Advertisements

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDAs website for reference purposes only. It.
U.S. Food and Drug Administration Notice: Archived Document. The content in this document is provided on the FDA’s website for reference purposes only.
Licensure Requirements for Cosmetic Laser Procedures By: Vickie L. Mickey, CT,CLHRP.
The IND and Clinical Trial Management Frances Richmond Director International Center for Clinical Trials.
Development of Guidance Documents Jennifer Scharpf, M. P. H
ORGANIZATION OF PUBLIC HEALTH IN NEVADA Randall Todd, DrPH Director, Epidemiology & Public Health Preparedness Washoe County Health District.
25 TAC Quality Assurance in a licensed ASC
CBER 1 Normal Source Plasma Donor Program Rosia E. Nesbitt, BS, SBB(ASCP), CQA(ASQ) Consumer Safety Officer CBER, OBRR, DBA September 16, 2009.
Data and Information Management of the Smallpox Vaccine Program Department of Health and Human Services Centers for Disease Control and Prevention December.
Use of Children as Research Subjects What information should be provided for an FP7 ethical review?
Public Health Measures
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
CBER Cooperative Manufacturing Arrangements (Contractors) Jennifer Jones Consumer Safety Officer CBER, OBRR, DBA September 15, 2009.
New Jersey School Districts By: Josefa Olson. Montclair Public Schools  Comprehensive community public school district that serves students in Kindergarten.
The Nurse Practice Act.  Defines the Nurse Practice Act and its function  Describes how the Nurse Practice Act applies to the RN Scope of Practice Objectives.
Coordinator University Clinical Research Pharmacy Investigational Drug Service (IDS) Marjorie Shaw Phillips, MS, RPh, FASHP Clinical Research Pharmacist.
Nic Dibble, Consultant School Social Work (608) Department of Public Instruction
Lisa Denney, MPH HRPP Assistant Director Melanie Mace, MA HRPP Education and Training Coordinator Bill Woods, PhD CAPS Policy and Ethics Core November.
International Research & Research Involving Children K. Lynn Cates, MD Assistant Chief Research & Development Officer Office of Research & Development.
CBER Review Considerations on Source Plasma Vaccination Programs Judy Ellen Ciaraldi BS, MT(ASCP)SBB, CQA(ASQ) CBER, OBRR, DBA September 16, 2009.
INDIAN HEALTH BOARD OF MINNEAPOLIS JOB DESCRIPTION HEALTH DISPARITIES SUPERVISOR EMPLOYEE: SUPERVISOR: UPDATED: DEPARTMENT: JOB SUMMARY This position exists.
POD 101 Introduction to Point of Dispensing Emergency Preparedness and Response Program & Community Health Services Version 1.1.
Testing People Scientifically.  Clinical trials are research studies in which people help doctors and researchers find ways to improve health care. Each.
Uintah School District Health Requirements and Services: Medical Treatment.
1 Disclosures © HIPAA Pros 2002 All rights reserved.
ORO Reviews: Frequent Findings Related to IRBs Bob Brooks Associate Director Research Compliance Education and Policy VHA Office of Research Oversight.
CBER Red Blood Cell Immunization Programs Judy Ellen Ciaraldi BS, MT(ASCP)SBB, CQA(ASQ) CBER, OBRR, DBA September 16, 2009.
Investigational New Drug Application (IND)
Planned Emergency Research Exception from Informed Consent Requirements September 2007.
FDA Science Board Drug Safety Initiative April 15, 2005 Rockville, MD RADM Steven Galson, MD, MPH Acting Director, Center for Drug Evaluation and Research.
Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.
University of Miami Office of Research Compliance Assessment Lynn E. Smith, JD, CIM, CIP Johanna Stamates, RN, BA, CCRC With assistance from Elizabeth.
Career Project By: Tiffany Miller. Description: Provide healthcare services typically performed by a physician, under the supervision of a physician,
Apheresis Blood Components
PATRICIA KERBY, MPA HUMAN SUBJECTIONS PROTECTION COMPLIANCE OFFICER OFFICE OF RESEARCH COMPLIANCE What are the FDA’s expectations in 2010?
1.Summary of Needs Analysis 2.Summary of Action Plan 3.Systems Analysis between Microsoft SharePoint® and OpenText Content Server 4.System Recommendation.
Standard 20 Accredited Program Administration. Required Materials Guide to Accreditation (add link) Standard 20 & associated guidelines Faculty Fact Sheet.
CBER 1 Review Considerations on Additional Centers under an Approved License Rosia E. Nesbitt, BS, SBB(ASCP), CQA(ASQ) Consumer Safety Officer CBER, OBRR,
CBER September 16, 2009 Review Considerations on Disease State Donor Programs Hoi-may Wong, BS, MT(ASCP)SBB Consumer Safety Officer CBER, OBRR, DBA.
The NCI Central IRB Initiative Third Annual Medical Research Summit Washington, D.C. March 2003.
CBER 1 Disease Associated Antibody Donor Program Rosia E. Nesbitt, BS, SBB(ASCP), CQA(ASQ) Consumer Safety Officer CBER, OBRR, DBA September 16, 2009.
U.S. Department of Transportation Pipeline and Hazardous Materials Safety Administration Approvals and Permits Division Isreal Mallard Transportation Specialist,
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Smallpox Vaccine Safety and Reporting Adverse Events Department of Health and Human Services Centers for Disease Control and Prevention December 2002.
Nursing Issues Panel Debbie Vierra, RN Delaware Valley Job Corps Center Region 1 Health and Wellness Conference May 14, 2004.
Management of Donors and Units that Test HBV NAT Positive: Current Considerations July 21, 2005 BPAC Meeting Robin Biswas, M.D. FDA/CBER/OBRR/DETTD.
HIT FINAL EXAM REVIEW HI120.
Copyright FDA Inspections: Where Do Things Go Wrong? Diana Naser RN, MS, CCRP Executive Director Clinical Research Administration Clinical Research.
Module C FDA Regulations Regulatory Documents Patricia E. Koziol 1Module C Final Version 10-apr-2010.
CBER Source Plasma Labeling Judy Ellen Ciaraldi BS, MT(ASCP)SBB, CQA(ASQ) CBER, OBRR, DBA September 16, 2009.
The NCI Central IRB Initiative Jacquelyn L. Goldberg, J.D. VA IRB Chair Training April 8, 2004.
CBER Common Problems on Source Plasma Inspections Judy Ellen Ciaraldi BS, MT(ASCP)SBB, CQA(ASQ) CBER, OBRR, DBA September 16, 2009.
Paul Kelly Facility Research Compliance Officer for the Ralph H. Johnson VA Medical Center.
Fellow Orientation Medical School Residency & Fellowship
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Human Specimen Repositories Requirements of 21 CFR Parts 50 & 56 PRIM & R May 5, 2004 Sally A. Hojvat, Ph.D. Director of Microbiology Devices Office of.
INTERNATIONAL SCIENCE AND ENGINEERING FAIR Rules and Guidelines 2016.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Vaccination POD Just-in-Time Training. A list of Vaccinators and Vaccinator Assistants at each station will be maintained by the Administrative Representative.
Collaborative Practice Agreements
Coordinator Course Managing Satellite Locations,
Bozeman Health Clinical Research
HIPAA Pros - Disclosures
University of Central Florida Office of Research & Commercialization
California Department of Public Health
MEDICAL BOARD OF CALIFORNIA
Streamlining IRB Procedures for Expanded Access
Proxy Caregiver Presented by: State Licensure Programs (PCH, PHCP, DTP) Healthcare Facility Regulation Division.
Direct Hire Authority (DHA) Opportunity
Presentation transcript:

CBER U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only. It was current when produced, but is no longer maintained and may be outdated.

CBER Medical Oversight in Source Plasma Centers Leslie Holness, MD Chief, Blood & Plasma Branch Division of Blood Applications FDA, Center for Biologics Evaluation & Research

CBER 3 FDA’s Mission is to Protect and Promote

CBER 4 Medical oversight in SP centers

CBER 5 SP Center Medical Director Must have a current state license (640.62) Must be trained on FDA regulations, cGMPs, recommendations, and center SOPs (606.20(b)) Must supervise the physician substitutes (640.63(a)) Should evaluate physicians substitutes’ performance of assigned duties Must select and schedule immunizations and evaluate clinical response (640.66) Must evaluate abnormal test results and determine whether donors may continue in the program (640.65(b)(2)(i))

CBER 6 Medical Supervision of RBC Immunization Program  Medical Director must: (640.66) – Certify the donor’s health to participate – Approve injection schedule – Select the antigen to be injected – Perform at least weekly evaluation and review of the donor immunization record – Evaluate clinical response (including monitoring reactions)  Medical Director must be on premises during RBC immunizations (640.62)

CBER 7 Physician Substitute A physician substitute program is approved by CBER to allow trained individuals to perform some of the duties of a physician provided the physician substitute is under the direct supervision of the on- site Center Physician/Medical Director

CBER 8 Physician Substitute Blood Memorandum: Physician Substitutes (August 15, 1988) Physician substitute program approved by CBER as alternative procedure to Submitted as a Prior Approval Supplement (601.12(b)) CBER approves program, not individual PS Physician substitute program should define the limits of authority and duties and provide specific instructions concerning handling medical emergencies & consulting the Medical Director Nursing (RN/LPN), EMT, physician assistant graduate Current state licensure or certification

CBER 9 Physician Substitute Maintains current CPR certification Has completed minimum 5 week training program Undergoes additional training if participates in immunization program Must be trained on FDA regulations, cGMPs, recommendations, and center SOPs [ (b)] May evaluate normal healthy donors, including donors in a pre-existing disease-associated antibody program

CBER 10 Physician Substitute Must be on premises during donor suitability determinations and collections (640.62) Not authorized to substitute for Medical Director in vaccine/RBC immunization, disease state, high risk and therapeutic exchange plasma programs Routinely they are not authorized to select or schedule immunizations Some physician substitutes are approved to do this as alternative procedure to Approval applies to vaccine immunization program using licensed vaccines according to the package insert Should not re-enter donors after an abnormal test result

CBER 11 Physician Substitute Duties Authorized to:  perform medical examinations and administer informed consents  Explain the plasmapheresis procedure  Determine donor suitability for normal healthy donors  Review SPEs (can accept normal SPEs, reject abnormal SPEs)  Give RBC immunization & vaccine injections  Manage medical emergencies and donor reactions  Counsel deferred donors  Communicate with Medical Director

CBER 12 Documentation  Evidence that Medical Director and physician substitute have received training required in (b)  Their evaluation of the donor’s suitability to donate and continue participation in donation programs ( (a & b(1))  Evidence they evaluated the records of adverse reactions that are required in (b)(1)(iii) – Records of adverse reactions related to immunization should be kept in a format that permits easy retrieval and analysis

CBER 13 Medical Oversight Summary  Medical Director must be active in plasma center donor programs – Physician substitute is not authorized to replace physician in some special plasma center donor programs  Medical Director is responsible for supervising physician substitute  Trained physician substitutes may perform some of the Medical Director duties – Physician substitute program is approved as a alternative procedure to under the provisions of

CBER 14 Medical Oversight Summary  Trained physician substitutes may perform some of the Medical Director duties – Normal Source Plasma donors – Pre-existing disease-associated antibody donors – Licensed vaccine immunization program, with additional training  Additional physician substitute training – Procedures relevant to the approved immunizing agents – Knowledge of hazards of immunizations to obtain appropriate informed consent – Details of how to handle unexpected adverse donor reactions by the immunizing agents

CBER 15